20.4 C
New York
Thursday, June 18, 2026

Tag: analysis

MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations

GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation...

KFSH Showcases Trusted AI as the Foundation for Scalable Healthcare Transformation at HLTH Europe 2026

RIYADH, Saudi Arabia, June 13, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will use its participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, to advance a clear message: artificial intelligence in healthcare will only scale when institutions can prove that it is safe, reliable, governed, and trusted by clinicians and patients.

Ripple’s XRP Meets AI Trading: AIXAlpha Launches Free AI Strategy Contracts with Daily Settlement

Join XRP and top assets through AI-driven automated strategies with daily settlement—no manual trading needed.
Join XRP and top assets through AI-driven automated strategies with daily settlement—no manual trading needed.

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

EpiCooler Product Information Updated As Consumer Interest In Portable AC Grows In 2026

Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --

An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026

SpaceX IPO Project Unlimited (Weiss Ratings’ Michael Robinson Disruptors & Dominators Newsletter) Elon’s Trillion Dollar Plan to Save AI

SPCX IPO live: Weiss Ratings' Disruptors & Dominators covers orbital AI supply chain research. 4 bonus reports. Weiss Ratings LLC.

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

VVT Med Provides Update on Management Cease Trade Order

VANCOUVER, BC, June 12, 2026 /CNW/ - VVT Med Inc. (TSXV: VVTM) (the "Company" or "VVT") is providing an update with respect to its...

Invesco Mortgage Capital Inc. June 2026 Dividend Announcement and May Financial Update

ATLANTA, June 12, 2026 /PRNewswire/ -- Invesco Mortgage Capital Inc. (NYSE: IVR) (the "Company") today announced that the Company declared a cash dividend of...

Allegheny Health Network’s Biomarker Moonshot Cancer Research Program Marks Five-Year Milestone, Enrolling More Than 11,000 Patients Across All Cancer Types

Systemwide research initiative uses blood‑based genomics to improve early detection and personalize cancer treatmentPITTSBURGH, June 12, 2026 /PRNewswire/ -- Allegheny Health Network (AHN) Cancer...

SpaceX IPO Warning (Crowdability Private Market Profits Newsletter) The Early-Stage Playbook with Exclusive Pre-IPO Research

Paradigm Press Private Market Profits: Matt Milner and Wayne Mulligan monthly investment research newsletter on private-market themes, 2026.

Morvulikent Officially Launches Its Advanced AI Trading Platform for the Next Generation of Automated Trading in 2026

New York City, June 12, 2026 (GLOBE NEWSWIRE) --

In 2026 Morvulikent has officially announced the launch of its new AI-powered trading platform, introducing a next-generation automated trading environment designed to simplify financial market participation through artificial intelligence, real-time data analysis, and intelligent automation.

Bloomberg Tax Report Examines Growing Debate Over State Data Center Tax Incentives

ARLINGTON, Va., June 12, 2026 /PRNewswire/ -- Bloomberg Tax today released a special report examining the growing scrutiny surrounding state tax incentives for data...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAnalysis